任军 , 杨朵 . 提高过继性T细胞免疫治疗临床疗效的新思考----肠道菌群与肿瘤免疫[J]. 北京大学学报（医学版）, 2020 , 52(2) : 204 -206 . DOI: 10.19723/j.issn.1671-167X.2020.02.002
| [1] | Cruz-Ramos M, Garcia-Foncillas J . CAR-T cell and personalized medicine[J]. Adv Exp Med Biol, 2019(1168):131-145. |
| [2] | Gorabi AM, Hajighasemi S, Sathyapalan T , et al. Cell transfer-based immunotherapies in cancer: A review[J]. IUBMB Life, 72(4):790-800. |
| [3] | 钱其军, 吴孟超 . 肿瘤过继细胞治疗----老故事新演绎[J]. 中国肿瘤生物治疗杂志, 2011,18(1):1-6. |
| [4] | Wculek SK, Cueto FJ, Mujal AM , et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2020,20(1):7-24. |
| [5] | Jiang N, Qiao G, Wang X , et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancrea-tic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073. |
| [6] | Wang X, Ren J, Zhang J , et al. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)[J]. Clin Transl Oncol, 2016,18(1):82-87. |
| [7] | Wang S, Wang X, Zhou X , et al.DC-CIK as a widely applicable cancer immunotherapy[J/OL].Expert Opin Biol Ther, ( 2020 -02-13). doi: 10.1080/14712598.2020.1728250. |
| [8] | Routy B, Gopalakrishnan V, Daillère R , et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018,15(6):382-396. |
| [9] | Goubet AG, Daillère R, Routy B , et al. The impact of the intestinal microbiota in therapeutic responses against cancer[J]. C R Biol, 2018,341(5):284-289. |
| [10] | Havel JJ, Chowell D, Chan TA . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer, 2019,19(3):133-150. |
| [11] | Sanmamed MF, Chen L . A paradigm shift in cancer immunotherapy: From enhancement to normalization[J]. Cell, 2018,175(2):313-326. |
| [12] | Li XV, Leonardi I, Iliev ID . Gut mycobiota in immunity and inflammatory disease[J]. Immunity, 2019,50(6):1365-1379. |
| [13] | Kamada N, Seo SU, Chen GY , et al. Role of the gut microbiota in immunity and inflammatory disease[J]. Nat Rev Immunol, 2013,13(5):321-335. |
| [14] | Round JL, Lee SM, Li J , et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota[J]. Science, 2011,332(6032):974-977. |
| [15] | Kim M, Galan C, Hill AA , et al. Critical role for the microbiota in CX3CR1 + intestinal mononuclear phagocyte regulation of intestinal T cell responses [J]. Immunity, 2018,49(1):151-163. |
| [16] | Fitzgibbon G, Mills KHG . The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention[J]. Eur J Immunol, 2020,50(3):326-337. |
| [17] | Karin M, Jobin C, Balkwill F . Chemotherapy, immunity and microbiota: a new triumvirate?[J]. Nat Med, 2014,20(2):126-127. |
| [18] | Ganal SC, Sanos SL, Kallfass C , et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota[J]. Immunity, 2012,37(1):171-186. |
| [19] | Abid MB, Shah NN, Maatman TC , et al. Gut microbiome and CAR-T therapy[J]. Exp Hematol Oncol, 2019(8):31. |
| [20] | Paulos CM, Wrzesinski C, Kaiser A , et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling [J]. J Clin Invest, 2007,117(8):2197-2204. |
| [21] | Dudley ME, Yang JC, Sherry R , et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens[J]. J Clin Oncol, 2008,26(32):5233-5239. |
| [22] | Uribe-Herranz M, Bittinger K, Rafail S , et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12[J]. JCI Insight, 2018,3(4):e94952. |
| [23] | Tanoue T, Morita S, Plichta DR , et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity[J]. Nature, 2019,565(7741):600-605. |
| [24] | Duell J, Dittrich M, Bedke T , et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL[J]. Leukemia, 2017,31(10):2181-2190. |
| [25] | Otoshi T, Nagano T, Tachihara M , et al. Possible biomarkers for cancer immunotherapy[J]. Cancers (Basel), 2019,11(7):935. |
/
| 〈 |
|
〉 |
